Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with locally advanced or metastatic urothelial bladder cancer (a cancer affecting the lining of the urinary tract, including the kidney pelvis, ureters, bladder, or urethra), confirmed by a tissue or cell sample
- People who are able to provide a tumour tissue sample that meets the trial's specific requirements
- People whose blood counts and organ function (such as liver and kidneys) are at adequate levels
- People who are reasonably active and able to carry out daily activities, rated 0 or 1 on a standard medical scale (meaning fully active or able to do light work)
- People with a life expectancy of at least 12 weeks
- People whose cancer can be measured on scans, using standard medical imaging criteria
Who may not be able to join:
- People who have received any approved cancer treatment within the 3 weeks before starting the trial
- People who have taken part in another clinical trial or received an experimental treatment within 28 days before enrolling
- People who have cancer that has spread to the brain or spinal cord area and is currently active or has not been treated
- People with cancer that has spread to the membranes surrounding the brain and spinal cord
- People who have had another type of cancer (other than urothelial bladder cancer) within the past 5 years
- People who are pregnant or breastfeeding
- People with serious heart or blood vessel disease
- People who have had a severe infection within 4 weeks before starting treatment
- People who have had a major surgical procedure (other than a procedure done to diagnose their cancer) within 4 weeks before starting treatment
- People who have had a severe allergic or hypersensitivity reaction to certain types of laboratory-made antibody treatments, or who are known to be allergic to the study drug (atezolizumab) or any of its ingredients (confirm with trial site)
- People with a history of autoimmune disease (conditions where the immune system attacks the body's own tissues)
- People who have previously received a stem cell transplant from a donor or a solid organ transplant
- People with a history of certain lung conditions, including scarring of the lung tissue, or who show signs of active lung inflammation on their screening scan
- People who test positive for HIV, active hepatitis B, active hepatitis C, or tuberculosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Phone: 86-13671121909
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival rate after receiving 4SCART infusion; Using CTCAE 4 standard to evaluate the level of adverse events after receiving 4SCART infusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.